FAP-targeted Affilin radiopharmaceutical

FAP-targeted Affilin radiopharmaceutical is an undisclosed preclinical targeted radionuclide therapy program being developed by ITM and Navigo Proteins for solid tumors. The therapeutic consists of a FAP-binding Affilin scaffold protein engineered using Navigo Proteins' Affilin platform and conjugated to a therapeutic radioisotope supplied by ITM. Its intended mechanism is selective binding to fibroblast activation protein on tumor-associated fibroblasts and potentially FAP-expressing tumor cells, delivering cytotoxic radiation to the tumor microenvironment. The program appears to remain at the research or preclinical stage, and no specific candidate name, brand name, or final isotope payload has been publicly disclosed in the provided context.

Other names

FAP-specific Affilin radiopharmaceuticalradiolabeled FAP-specific AffilinFAP-targeted Affilin